194 related articles for article (PubMed ID: 27518544)
21. Intravitreal Anti-Vascular Endothelial Growth Factor Cost Savings Achievable with Increased Bevacizumab Reimbursement and Use.
Glasser DB; Parikh R; Lum F; Williams GA
Ophthalmology; 2020 Dec; 127(12):1688-1692. PubMed ID: 32544559
[TBL] [Abstract][Full Text] [Related]
22. High Variation of Intravitreal Injection Rates and Medicare Anti-Vascular Endothelial Growth Factor Payments per Injection in the United States.
Erie JC; Barkmeier AJ; Hodge DO; Mahr MA
Ophthalmology; 2016 Jun; 123(6):1257-62. PubMed ID: 26976701
[TBL] [Abstract][Full Text] [Related]
23. Safety and complications of intravitreal injections performed in an Asian population in Singapore.
Xu Y; Tan CS
Int Ophthalmol; 2017 Apr; 37(2):325-332. PubMed ID: 27236451
[TBL] [Abstract][Full Text] [Related]
24. A licence to cure.
Aronson JK; Ferner RE
BMJ; 2015 Apr; 350():h1723. PubMed ID: 25834026
[No Abstract] [Full Text] [Related]
25. Canadian preference and trends survey results for anti-VEGF treatment of macular edema.
Rayat JS; Grewal PS; Whelan J; Tennant MT; Choudhry N
Can J Ophthalmol; 2016 Jun; 51(3):233-7. PubMed ID: 27316276
[No Abstract] [Full Text] [Related]
26. The diabetic retinopathy clinical research network analysis of the cost-effectiveness of aflibercept, bevacizumab and ranibizumab for the treatment of diabetic macular oedema and its application in Spain.
Navarro-Navarro A; Salom D; Martínez-Toldos JJ; Udaondo P; Fernández-Martínez C; Gutiérrez-Arias L; Hervás A; Rodrigo R
Arch Soc Esp Oftalmol; 2017 May; 92(5):245-246. PubMed ID: 28215618
[No Abstract] [Full Text] [Related]
27. Higher priced drugs are not cost effective for diabetic macular edema, US study finds.
McCarthy M
BMJ; 2016 Jun; 353():i3253. PubMed ID: 27283845
[No Abstract] [Full Text] [Related]
28. Long-Term Effect of Anti-VEGF Agents on Intraocular Pressure in Age-Related Macular Degeneration.
Beato J; Pedrosa AC; Pinheiro-Costa J; Freitas-da-Costa P; Falcão MS; Melo A; Estrela-Silva S; Falcão-Reis F; Carneiro ÂM
Ophthalmic Res; 2016; 56(1):30-4. PubMed ID: 27046391
[TBL] [Abstract][Full Text] [Related]
29. [Anti-VEGF therapy for neovascular age-related macular degeneration -therapeutic strategies: statement of the German Ophthalmological Society, the German Retina Society and the Professional Association of Ophthalmologists in Germany - November 2014].
Deutsche Ophthalmologische Gesellschaft
Ophthalmologe; 2015 Mar; 112(3):237-45. PubMed ID: 25739373
[No Abstract] [Full Text] [Related]
30. [Interest of optical coherence tomography performed immediately before intravitreal injection of anti-VEGF in exudative AMD].
Moyal L; Cohen SY; Pedinielli A; Semoun O; Lalloum F; Jung C; Souied E
J Fr Ophtalmol; 2015 Sep; 38(7):573-9. PubMed ID: 25997681
[TBL] [Abstract][Full Text] [Related]
31. Avastin is as effective as Lucentis for wet AMD and could save NHS 84m pound a year, study shows.
Hawkes N
BMJ; 2012 May; 344():e3275. PubMed ID: 22573655
[No Abstract] [Full Text] [Related]
32. Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness.
Shah CP; Heier JS
Ophthalmic Surg Lasers Imaging Retina; 2016 Sep; 47(9):836-9. PubMed ID: 27631479
[TBL] [Abstract][Full Text] [Related]
33. Comparison of anti-VEGF therapies on fibrovascular pigment epithelial detachments in age-related macular degeneration.
Au A; Parikh VS; Singh RP; Ehlers JP; Yuan A; Rachitskaya AV; Sears JE; Srivastava SK; Kaiser PK; Schachat AP; Martin DF; Modi Y
Br J Ophthalmol; 2017 Jul; 101(7):970-975. PubMed ID: 27913442
[TBL] [Abstract][Full Text] [Related]
34. Aflibercept vs. Ranibizumab: cost-effectiveness of treatment for wet age-related macular degeneration in Sweden.
Panchmatia HR; Clements KM; Hulbert E; Eriksson M; Wittrup-Jensen K; Nilsson J; Weinstein MC
Acta Ophthalmol; 2016 Aug; 94(5):441-8. PubMed ID: 27061020
[TBL] [Abstract][Full Text] [Related]
35. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor.
Moon DRC; Lee DK; Kim SH; You YS; Kwon OW
Korean J Ophthalmol; 2015 Aug; 29(4):226-32. PubMed ID: 26240506
[TBL] [Abstract][Full Text] [Related]
36. Comparison of Outcomes and Costs of Ranibizumab and Aflibercept Treatment in Real-Life.
Schmid MK; Reich O; Faes L; Boehni SC; Bittner M; Howell JP; Thiel MA; Signorell A; Bachmann LM
PLoS One; 2015; 10(8):e0135050. PubMed ID: 26241852
[TBL] [Abstract][Full Text] [Related]
37. VEGF inhibitors for AMD and diabetic macular edema.
Med Lett Drugs Ther; 2015 Mar; 57(1464):41-2. PubMed ID: 25758545
[No Abstract] [Full Text] [Related]
38. Long-term effect of anti-vascular endothelial growth factor injections on intraocular pressure.
Nariani A; Williams B; Hariprasad SM
Indian J Ophthalmol; 2016 Sep; 64(9):643-647. PubMed ID: 27853011
[TBL] [Abstract][Full Text] [Related]
39. [Budget impact of the incorporation of second-line drug treatment for diabetic macular edema in the Brazilian Unified National Health System from the perspective of the Minas Gerais State Health Department, Brazil].
Izidoro JB; Piazza T; Andrade EIG; Alvares-Teodoro J
Cad Saude Publica; 2019 Aug; 35(8):e00145518. PubMed ID: 31460612
[TBL] [Abstract][Full Text] [Related]
40. Effect of Regulatory Requirement for Patient-Specific Prescriptions for Off-Label Medications on the Use of Intravitreal Bevacizumab.
Holfinger S; Miller AG; Rao LJ; Rowland DY; Hornik JH; Miller DG
JAMA Ophthalmol; 2016 Jan; 134(1):45-8. PubMed ID: 26540671
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]